|
 |
CerezymeThis page contains recent news articles, when available, and an overview of Cerezyme but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Cerezyme (when available) Gaucher disease is characterized by a functional deficiency in Beta-glucocerebrosidase enzymatic activity and the resultant accumulation of lipid glucocerebroside in tissue macrophages which become engorged and are termed Gaucher cells. Gaucher cells are typically found in liver, spleen and bone marrow. This can lead to an enlarged spleen and liver (hepatosplenomegaly). Secondary hematologic sequelae include severe anemia and thrombocytopenia. Injections of imiglucerase into Gaucher disease patients leads to elevated serum levels of the enzyme and reduction in the accumulation of glucocerebroside leading to reduced anemia and thrombocytopenia, reduced spleen and liver size, and decreased cachexia For treatment of Gaucher's disease (deficiency in glucocerebrosidase) Mechanism Of Action: Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids. News Articles on Imiglucerase More contamination troubles for Genzyme - 14 Nov 2009 Cerezyme treats Gaucher disease, which causes fatty substances to accumulate in the liver, spleen, and other organs. Fabrazyme treats Fabry disease, ... Boston Globe National business briefs - 14 Nov 2009 The drugs, which are used to treat rare enzyme disorders, include: Cerezyme, Fabrazyme, Myozyme, Aldurazyme and Thyrogen. ... NewsOK.com US stocks advance - 14 Nov 2009 US regulators said some lots of the company's Cerezyme, Fabrazyme, Myozyme, Aldurazyme, and Thyrogen may be contaminated with stainless steel fragments, ... The Age Genzyme begins Phase 3 clinical trial - Oct 20, 2009 Genzyme currently markets Cerezyme, an injectable treatment for Gaucher disease, an enzyme deficiency in which fatty substances accumulate in the spleen, ... Boston Globe Genzyme Corporation - SWOT Analysis - New Report Published - Nov 12, 2009 The increase was primarily due to higher sales of Cerezyme ((imiglucerase for injection), Fabrazyme (agalsidase beta), Renagel (sevelamer hydrochloride), ... OfficialWire (press release) FDA will fast-track review of Shire's Gaucher disease treatment - Nov 4, 2009 Since this summer, the world's most popular Gaucher treatment, Cerezyme, has been difficult for obtain. The difficulties came after Cerezyme manufactuer ... Boston Herald UPDATE 1-U.S. FDA: Some Genzyme drugs contaminated - Nov 13, 2009 The FDA said the affected products included Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, Myozyme for Pompe disease, Aldurazyme for ... 路透中国 Protalix BioThera (PLX) May Have a Winner with Gaucher Drug prGCD - Nov 13, 2009 PrCGD would be a prime competitor with Genzyme's (NASDAQ: GENZ) Cerezyme. The method of producing enzymes for Protalix is fairly low-cost as well, ... StreetInsider.com (subscription) Genzyme slides on outlook; Antigenics plunges 40% - Oct 21, 2009 Genzyme added that it has resumed production of its top-selling products Cerezyme and Fabrazyme at the re-mediated plant. It expects to begin shipping ... MarketWatch Genzyme Corporation Q3 2009 Earnings Call Transcript - Oct 21, 2009 But the dominant factors clearly are the Allston production and restart of the plant and supply of Cerezyme, Fabrazyme and Myozyme or Lumizyme for that ... Seeking Alpha (blog) Shire: We Have US Gaucher Patients On Vela - CEO - Oct 30, 2009 About 4000 patients have been affected by a shortage of Cerezyme, the only other US-approved drug for Gaucher disease. The shortage was caused by a shutdown ... Wall Street Journal Genzyme plant gets OK from European regulators - Nov 3, 2009 Shortages of the two primary drugs made at the plant, Fabrazyme for Fabry disease and Cerezyme for Gaucher disease, have remained a problem since the ... Bizjournals.com Genzyme Could Get 'ERT' as Pharma Makes Gaucher Bids - Nov 4, 2009 ...s market leader Cerezyme (imiglucerase). But New York-based Pfizer, fresh off its $68 billion acquisition of Wyeth, also might be interested in the ... BioWorld Online Rising market tide fails to lift some Mass. firms - Nov 12, 2009 Genzyme expects to begin shipping the two drugs, Cerezyme and Fabrazyme, at the end of this month and in December, a spokesman said yesterday. ... Boston Globe Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX) - Nov 10, 2009 We think Cerezyme will lose major market share due to the shortage and damaged Gaucher's community relationships. We think Uplyso data gives good proof of ... StreetInsider.com (subscription) Genzyme: Focusing on Lumizyme Approval - Oct 30, 2009 However, I believe that the main uncertainty remaining from this manufacturing setback is how Cerezyme revenues will bounce back when full production will ... Seeking Alpha (blog) The Ticker - Nov 4, 2009 The drug would compete with Genzyme's Cerezyme, which is in short supply because of manufacturing problems. Ernie Boch Jr.'s Norwood dealership sold 417 ... Boston Herald Report: Pfizer may make a bid for Protalix - Nov 2, 2009 A likely contender to Cerezyme, the drug is being readied for an NDA after Genzyme announced problems with contamination at the facility that makes its ... FierceBiotech Shire's Gaucher drug gets FDA priority review - Nov 5, 2009 If approved, the drug candidate would serve as an alternative to Genzyme's Cerezyme drug, which has faced shortages due to Genzyme's earlier manufacturing ... Mass High Tech Genzyme production in 'recovery mode' - Oct 22, 2009 Around $200 million in lost sales was attributable purely to the Cerezyme shortage. In tandem with re-validating the four 2000-litre bioreactors at the ... Pharmafocus GMP deviators keep paying - Nov 4, 2009 The company has since resumed operations at the plant, which is used to make Cerezyme and Fabrazyme. It says it expects to begin shipping both before year's ... FiercePharma Manufacturing Shire celebrates as FDA backs Vyvanse exclusivity - Oct 27, 2009 Collins Stewart noted that last week Genzyme commented that it thinks less than 100 patients have switched from Cerezyme to date. By Kevin Grogan. Pharma Times Genzyme tests new Gaucher drug - Oct 21, 2009 Genzyme has launched a phase 3 trial for a Gaucher disease drug candidate that could treat some patients now affected by the company's shortage of Cerezyme, ... Boston Business Journal Genzyme Releases 3Q Financial Results - Oct 26, 2009 In a release on October 21, the Company noted that results reflect the impact of the temporary interruption in production of Cerezyme (imiglucerase for ... Trading Markets (press release) FDA Said Pieces Of Steel, Rubber, Fiber Found In Drugs Made By Genzyme (GENZ) - Nov 13, 2009 The drugs include Cerezyme, Fabrazyme, Myozyme, Aldurazyme, and Thyrogen. The FDA estimated that contamination only affected about 1% of the company's ... Trading Markets (press release) Genzyme Begins Enrollment in Phase 3 Trials of Oral Capsule for Gaucher Disease - Oct 23, 2009 Encore is a randomized, open-label study for adult patients with Gaucher disease type 1 designed to compare Genz-112638 to Cerezyme (imiglucerase for ... Trading Markets (press release) FDA OKs Shire's Replagal treatment protocol; BLA filing soon - Oct 22, 2009 ...shortage of Fabrazyme (agalsidase beta) - the only marketed Fabry disease drug in the US - as well as Cerezyme (imiglucerase) for Gaucher disease. ... Pharma Times Plant shutdown weighs on Genzyme earnings - Oct 21, 2009 Genzyme added that it has resumed production of its products Cerezyme and Fabrazyme at the remediated plant. It expects to begin shipping Cerezyme in late ... MarketWatch Wall Street Breakfast: Must-Know News - Nov 2, 2009 If approved, it would compete with Genzyme (GENZ) blockbuster Cerezyme. The cost of doing better. UAW rank-and-file dealt Ford (F) a fatal blow, ... Seeking Alpha (blog) Actelion Pharmaceuticals Ltd (CH) - Actelion announces 9-month financial ... - Oct 21, 2009 ...(miglustat) to minimize the impact of the supply shortage of imiglucerase (produced and marketed by Genzyme Corporation under the brand name Cerezyme®). ... PharmaLive.com (press release) Sanofi Expects Swine-Flu Vaccine to Boost Sales - Oct 30, 2009 The US Food and Drug Administration, or FDA, asked Shire to step in following a shortage of Gaucher treatment Cerezyme caused by manufacturing problems at ... Wall Street Journal חדשות טובות עבור פרוטליקס? חשש ×›×™ תרופות של חברת ×’'× ×–×™×™×? זוהמו במתכת וגומי - Nov 13, 2009 ...בחודש ×™×•× ×™ הודיעה ×’'× ×–×™×™×? על השבתת הייצור של שתיי×? מתרופותיה ×”× ×ž×›×¨×•×ª ביותר - Cerezyme ו-Fabrazyme - עקב זיהו×? במפעל של החברה בבוסטון. ... The Marker Zacks Bull and Bear of the Day Highlights: McDonald's, Genzyme, Berkshire ... - Nov 4, 2009 The shutdown is a major setback as three drugs -- including key product Cerezyme -- were being manufactured at the facility. Although Genzyme has resumed ... Business Wire (press release) Allergan Q3 Profit Rises; Lifts FY09 Adj. EPS Outlook - Update - Oct 29, 2009 ...manufacturing facility in Boston that resulted in restricted supplies of the company's Gaucher disease drug Cerezyme and Fabry disease drug Fabrazyme. ... Trading Markets (press release) Quarterly - PRESS RELEASE: BB BIOTECH: Positive performance in the third quarter - Oct 29, 2009 Genzyme is progressing well to resolve its manufacturing problems for its key product Cerezyme, approved for the treatment of a rare genetic lysosomal ... Ad-Hoc-News (Pressemitteilung) El niño que tiene el bazo como un adulto - Nov 12, 2009 Actualmente, Genzyme es el laboratorio encargado de la fabricación de Cerezyme, el tratamiento de sustitución enzimática que se utiliza para estos enfermos. ... El Confidencial Nieuw behandelingsadvies Cerezyme - Oct 28, 2009 28 oktober 2009 - Nieuw behandelingsadvies Cerezyme In vervolg op ons webbericht van 17 augustus 2009 zijn door de firma Genzyme nieuwe, ... Nieuws.nl Genzyme 盈馀低於预期，股价下跌4% - Oct 21, 2009 ...å…¬å?¸é¢„ä¼°2009å¹´æ¯?股盈馀约2.26美元，先å‰?预测2.85-2.9美元，市场预期2.46美元，å??æ˜ Cerezyme任列在制å“?原料的决议丶Allston工厂改建æˆ?本丶管ç?†å®¢æˆ·åº“å˜ã€‚ ... 凤凰网 Genzyme下调2009财年盈馀预期 - Oct 21, 2009 ...由於旗舰产å“?Cerezyme的一座主è¦?工厂的临时关é—和修å¤?，生化科技公å?¸Genzyme Corp(GENZ)公布第三财å£èŽ·åˆ©å¤§å¹…下滑。该公å?¸å½“å£èŽ·åˆ©ä»ŽåŽ»å¹´å?ŒæœŸçš„1.20亿美元，æ¯?股盈馀42 ... 凤凰网 Genzyme下調2009財年盈餘é ?期 - Oct 21, 2009 ...由於旗艦產å“?Cerezyme的一座主è¦?å·¥å» çš„è‡¨æ™‚é—œé–‰å’Œä¿®å¾©ï¼Œç”ŸåŒ–ç§‘æŠ€å…¬å?¸Genzyme Corp(GENZ)公佈第三財å£ç?²åˆ©å¤§å¹…下滑。該公å?¸ç•¶å£ç?²åˆ©å¾žåŽ»å¹´å?ŒæœŸçš„1.20億美元，æ¯?股盈餘42 ... 鉅亨網 供应告急 åœ¨ç ”æˆˆè°¢ç—…è?¯ç¼ºå¤±æˆ?为焦点 - Oct 28, 2009 ...ã€?æ…§è?ªåˆ¶è?¯å·¥ä¸šç½‘】最近，由于å?¥èµžï¼ˆGenzyme）公å?¸ç”Ÿäº§â€œé‡?磅炸弹â€?è?¯ç‰©é…¶æ›¿ä»£æ²»ç–—è?¯ç‰©ä¼Šç±³è‹·é…¶ï¼ˆImigluceraseã€?Cerezymeï¼‰çš„åŽ‚æˆ¿æ„ŸæŸ“ç—…æ¯’é€ æˆ?该è?¯ç‰©ä¾›åº”ç´§å¼ ï¼Œè¿™ä¸€äº‹ä»¶ ... 慧聪网 וול סטריט בדרך לשבוע ×©× ×™ של עליות: × ×?סד"ק עולה ב-1%; דולר ×’'× ×¨×œ עולה ב-8% ביו×? ... - Nov 13, 2009 ...התרופות, בהן כמה מהתרופות ×”× ×ž×›×¨×•×ª ביותר של החברה, שהופצו ו×?שר קיי×? חשש לזיהו×? בחלקן הן: Cerezyme, Fabrazyme, Myozyme, Aldurazyme ו-Thyrogen. ... The Marker è?¯ä»¥ç¨€ä¸ºè´µ - Nov 3, 2009 ...ä¸å›½å¸‚场，区别在于，å?Œè¡Œä»¬è·ƒè·ƒæ¬²è¯•åœ°å‡ºå”®å¼•ä»¥ä¸ºå‚²çš„è?¯å“?，而å?¥èµžå?´åœ¨å…?费奉é€?——针对患有罕è§?的戈谢æ°?症的100多å??ä¸å›½ç—…人æ??èµ å…¶æ ¸å¿ƒäº§å“?æ€?而赞（Cerezyme）。 ... 环球企业家 Genzyme: Πτώση κεÏ?δών και εσόδων το γ΄ Ï„Ï?ίμηνο - Oct 21, 2009 η πτώση των κεÏ?δών οφείλεται κατά κÏ?Ï?ιο λόγω στο Ï€Ï?οσωÏ?ινό κλείσιμο του εÏ?γοστασίου που παÏ?ήγαγε τα σημαντικότεÏ?α σκευάσματα Cerezyme και Fabrazyme. Capital.gr 美股早盘三大指数å°?幅上涨 - Oct 21, 2009 ...由於旗舰产å“?Cerezyme的一座主è¦?工厂的临时关é—和修å¤?，生化科技公å?¸Genzyme Corp(GENZ)公布第三财å£èŽ·åˆ©å¤§å¹…下滑。å£åº¦è?¥æ”¶ä»ŽåŽ»å¹´å?ŒæœŸçš„11.6亿美元下é™?至10.6亿美元。 ... 凤凰网 辉瑞或将收è´Protalix - Nov 4, 2009 ...如果获得相关部门批准，å??为Uplyso的该è?¯å°†å?¯ä»¥ä¸ŽGenzymeå…¬å?¸æŽ¨å‡ºçš„销售é‡?最大的è?¯ç‰©Cerezyme竞争。 以色列Biocellå…¬å?¸æ‹¥æœ‰Protalix19%çš„è‚¡æ?ƒã€‚ ... 生物谷 Pharma news - Nov 4, 2009 Se sarà approvato, il prodotto, chiamato Uplyso, andrebbe a competere con Cerezyme di Genzyme. L'israeliana Biocell possiede il 19% di Protalix ma il Chief ... Pharma Marketing BB Biotech, terzo trimestre 2009 positivo per le società del gruppo - Oct 29, 2009 Genzyme sta compiendo significativi progressi per risolvere i problemi di manifattura del suo prodotto di punta Cerezyme, approvato per il trattamento di ... La Repubblica מדווחות בולטות בוול סטריט: בו×?×™× ×’ רושמת הפסד של מעל 1.6 מילי×?רד דולר - Oct 21, 2009 ...חברת התרופות ×’'× ×–×™×™×? (סימול: GENZ) סבלה ברבעון ×”×?חרון מסגירה ×–×ž× ×™×ª של מפעל ייצור של התרופה המובילה שלה, Cerezyme. לפיכך, החברה רשמה רווח של 16 מיליון דולר, ... Bizportal BB BIOTECH: Positive Performance im dritten Quartal 2009 - Oct 28, 2009 Genzyme erzielte gute Fortschritte bei der Behebung von Produktionsproblemen für sein Schlüsselprodukt Cerezyme, das zur Behandlung der seltenen erblichen ... PR-Inside.com (Pressemitteilung) Cerezyme sales lift Genzyme in quarter - Jan 12, 2005 Genzyme Corp., the biotech firm expanding into the market for cancer treatments, said fourth-quarter revenue rose 23 percent to $591 million on higher sales ... Boston Globe Cutting Dosage of Costly Drug Spurs a Debate - Mar 16, 2008 The drug in question, Cerezyme, is used to treat a rare inherited enzyme deficiency ... In that sense, the dispute over Cerezyme could be a sign of the ... New York Times Study shows Genzyme's Cerezyme may be effective - Jan 16, 2007 Genzyme Corp. is promoting results from a new clinical study that apparently validate long-term use of its enzyme replacement drug Cerezyme. ... Bizjournals.com Genzyme's Gaucher disease pill promising in trial - May 16, 2007 Currently, Genzyme's own drug, Cerezyme, which is given once every two weeks by infusion, ... Genz-112638 works through a different mechanism than Cerezyme. ... Reuters COMPANY LOSES UK RULING ABOUT CEREZYME DISCOUNT - Oct 5, 2005 A long-running dispute between Genzyme Corp. and the British government has ended with a British agency's ruling that the company must offer home-care ... $2.95 - Boston Globe - NewsBank Analysts React To Genzyme Earnings - Jul 12, 2006 ..."We expect sales of [Renagel, Cerezyme, Fabrazyme] to remain strong, and we are positive on the potential for Myozyme, as well as several other late-stage ... Forbes Genzyme's Revenue Set to Climb - Jan 9, 2006 Sales of one of its top drugs, Cerezyme, climbed 6% to $232 million. Cerezyme is a treatment for Gaucher disease, an inherited condition that causes the ... TheStreet.com - TheStreet.com (subscription) Genzyme reports lower profit on Isis deal charges - Apr 23, 2008 Sales of the company's best-selling product, Cerezyme, a treatment for Gaucher disease, increased 15% to $304.3 million. Its second best-selling therapy, ... MarketWatch Genzyme battles an old adversary. - Jan 25, 2005 At the center of the tiff is Genzyme's Cerezyme. In 2004, the company sold $839 million of Cerezyme, accounting for 37 percent of Genzyme's total revenue. ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme Sticks With Forecast - Feb 15, 2006 Genzyme expects sales of Cerezyme to grow to $970 million to $980 million in 2006 from $932 million last year. Synvisc sales are projected to be $255 ... TheStreet.com - TheStreet.com (subscription) Fleeing Biotechs? Not So Fast - Apr 9, 2007 ...s (GENZ ) Cerezyme for Gaucher's disease tops $200000. Genentech Inc.'s (DNA ) Avastin, first approved for colon cancer, can cost $100000 per year. ... BusinessWeek Genzyme 3rd-qtr sales rise; profit falls on charge - Oct 22, 2008 Sales of Cerezyme, for Gaucher disease, rose 8 percent to $309.3 million. (Reporting by Toni Clarke, editing by Dave Zimmerman and Maureen Bavdek) Reuters Genzyme profits leap 58 percent in second quarter. - Jul 15, 2005 Though much of Genzyme's sales still come from Cerezyme, a treatment for a rare ... "It used to be a company of mainly Cerezyme, but now there's five or six ... Free with registration - Boston Globe - AccessMyLibrary.com Biotechs Find Riches in Orphaned Niches - Jun 15, 2006 While the drug prices may seem compelling for drug companies, consider that Lipitor brought in more than $12 billion last year for Pfizer, while Cerezyme ... TheStreet.com - TheStreet.com (subscription) Genzyme Boosts Second-Quarter Profit, Raises Forecast - Jul 25, 2007 ...``Cerezyme continues to put up really good numbers. ... Revenue from Cerezyme rose 11 percent to $283 million for the quarter, from $254 million a year ... Bloomberg Genzyme Provides Bullish Guidance - Jan 8, 2008 Sales of Gaucher's disease treatment Cerezyme also beat consensus targets with $301 million in sales for the quarter. Coming in at the top end of estimates, ... TheStreet.com - TheStreet.com (subscription) Genzyme seeks OK for Pompe disease drug.(Myozyme) - Jul 30, 2005 It would join Cerezyme, which has 4400 patients, and a newer drug called ... By far the largest is Cerezyme, with about $900 million in sales a year. ... Free with registration - Boston Globe - AccessMyLibrary.com Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions - Oct 12, 2006 Sales of Genzyme's biggest seller, Cerezyme for Gaucher's disease, rose 5.8 percent, accounting for ... Cerezyme sales were $252.2 million in the quarter. ... Bloomberg Genzyme earnings rise on higher drug sales - Apr 25, 2007 Sales of Cerezyme, the company's drug to treat Gaucher disease, which causes enlargement of the liver and spleen, rose to $263.8 million from $239 million. ... Reuters Genzyme Delivers Earnings Beat - Oct 24, 2007 ...sales of Fabrazyme Fabry disease increased 12% year over year to $104.6 million; and sales of Guacher disease drug Cerezyme grew 13% to $286.1 million. ... TheStreet.com - TheStreet.com (subscription) Event Brief of Q3 2005 Genzyme Corporation Earnings Conference Call -... - Oct 18, 2005 The Co. is continuing to invest in Cerezyme and in Gaucher disease. 1. ... Cerezyme revenue came in at $238m. 1. This product line continues to mature and ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genzyme looks to China - Apr 22, 2008 Genzyme's products include the kidney disease treatment Renvela and several treatments for genetic disorders, including Gaucher disease treatment Cerezyme ... Boston Globe Specialty drugs seen driving up premiums - Dec 4, 2006 One specialty drug is Cerezyme , made by Genzyme Corp. and used to treat Gaucher disease. The genetic disorder causes enlarged internal organs and affects ... Boston Globe … Publication of Study Showing Impact of Cerezyme on Bone Health for... - Jan 15, 2007 Cerezyme, an enzyme replacement therapy, is the standard of care for patients ... To evaluate the effect of long-term Cerezyme use on bone mineral density, ... webwire.com High-priced drugs raising questions - Mar 16, 2008 The drug, Cerezyme, is used to treat a rare inherited enzyme deficiency called Gaucher disease. Some researchers say that for many patients as little as ... United Press International Genzyme Receives Approval for Additional Manufacturing at Ireland... - Jul 24, 2006 Genzyme currently produces Cerezyme at its flagship manufacturing facility in Allston, MA. The company plans to use the Waterford facility for additional ... Free with registration - PR Newswire - AccessMyLibrary.com When a Drug Costs $300,000 - Mar 23, 2008 Only about 5000 people around the world are taking Cerezyme, including about ... The experience with Cerezyme and other biological drugs defies conventional ... New York Times … Publication of Study Showing Impact of Cerezyme on Bone Health for... - Jan 15, 2007 Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Why Genzyme Can Charge So Much for Cerezyme - Nov 16, 2005 By GEETA ANAND. Why is the price of Genzyme Corp.'s drug for Gaucher disease $200000 a year for the average patient? The reason is simple -- Genzyme charges ... Subscription - Wall Street Journal Online - Dow Jones & Company Digital Influence Group Partners with Genzyme, Using Social Media to ... - Aug 16, 2007 Genzyme Vice President of Emerging Markets Tomye Tierney will document her experiences in distributing Genzyme's enzyme replacement therapy, Cerezyme, ... Free with registration - Business Wire - AccessMyLibrary.com Genzyme, Amgen, Novartis sell orphan blockbusters - Mar. 15, 2007 - Mar 15, 2007 Cerezyme, Genzyme's Gaucher drug, is one of the world's most expensive drugs. ... About 5000 patients take Cerezyme, according to company spokesman Dan ... CNNMoney.com €20m R&D investment for Waterford - Jul 9, 2007 Genzyme Ireland currently manufactures three products – Renagel tablets as well as Cerezyme and Thymoglobulin injections – at its Waterford-based fill and ... Siliconrepublic.com Genzyme: Geared for Growth - Jun 11, 2007 In the first quarter of 2007, Cerezyme accounted for 32% of total revenues. We expect Cerezyme sales to account for roughly 30% of full-year 2007 sales, ... BusinessWeek Rare diseases, high drug prices and occasional profits. - Jul. 8, 2005 - Jul 8, 2005 The company's top-selling drug, Cerezyme, treats 4500 patients with Gaucher and ... The Boston-based biotech projects this year's Cerezyme sales to top $890 ... CNNMoney.com VeselÄ«bas ministrija: zÄ“nam ar GoÅ¡Ä“ slimÄ«bu pamatoti atteikts finansÄ“t... - May 22, 2008 ...tiesÄ«ga Å¡im pacientam pieÅ¡Ä·irt vien daļu naudas, tÄ?pÄ“c tika pieņemts lÄ“mums kompensÄ“t zÄ?ļu Imiglucerase (Cerezyme) vienu iepakojumu 83,33 latu apmÄ“rÄ?. ... NeatkarÄ«gÄ? RÄ«ta AvÄ«ze Donations tie drug firms and nonprofits: Many patient groups reveal... - May 28, 2006 He acknowledged that the group was so important for Cerezyme marketing that if it didn't exist, Genzyme would have looked for another. ... Free with registration - Philadelphia Inquirer - AccessMyLibrary.com Genzyme第一å£åº¦ç›ˆåˆ©é™?至1.453亿美元 - Apr 23, 2008 ...该公å?¸ç¬¬ä¸€å¤§ç•…销è?¯ã€?高雪æ°?症治疗è?¯ç‰©Cerezyme第一å£åº¦é”€å”®é¢?æ??高15%，至3.043亿美元。 第二大畅销è?¯Renagel销售é¢?较去年å?ŒæœŸå¤§å¢ž23%，至1.687亿美元。 ... 新浪网 Donations link drug firms to nonprofit patient groups. - Jun 8, 2006 He acknowledged that the group was so important for Cerezyme marketing that if it didn't exist, Genzyme would have looked for another. ... Free with registration - Philadelphia Inquirer - AccessMyLibrary.com United Kingdom, Anti-trust/Competition, CAT imposes competition... - Apr 10, 2005 The fine concerned Genzyme's product Cerezyme which was until recently the only treatment for Gaucher disease, a rare inherited disorder. ... Mondaq News Alerts - Mondaq News Alerts (Registration) It costs how much? - May 6, 2007 Cerezyme, which treats a rare genetic disease, is used by fewer than 5000 ... Cerezyme and Elaprase are extreme cases that highlight a growing concern about ... Boston Globe Genzyme blog touts Gaucher drug giveaways - Jan 28, 2008 She then describes how Cerezyme has benefited a brother and sister with ... Genzyme's Cerezyme drug is the enzyme-replacement treatment that is given to ... Mass High Tech Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue - Jan 9, 2006 For the year, Cerezyme sales were $933 million, up 11 percent from $839 million ... Genzyme's dependence on Cerezyme sales to drive its growth has decreased ... webwire.com Disruptions to continue on Amtrak Boston-NY runs - Oct 5, 2005 The ruling marks a rare setback for Genzyme's long-standing policy to offer no discounts on its enzyme-replacement drugs like Cerezyme, which treat rare ... Boston Globe Genzyme "outperform" - Jan 9, 2008 USD) und bei "Cerezyme" mit einem Umsatz von 301 Mio. USD (Analystenprognose: 280 Mio. USD). Für das Jahr 2008 habe das Unternehmen die bisherige ... AktienCheck Genzyme Corp - Jun 19, 2006 Its largest selling product is Cerezyme, a drug to treat Gaucher ... The company's lead therapeutic product is Cerezyme, an enzyme replacement therapy for ... $35.00 - Stock Reports - Standard & Poor's Challenges in Developing Therapies for Rare Diseases Including … - Jun 9, 2005 Approximately half of Genzyme's 2003 revenue came from $740 million in sales of Cerezyme (Genzyme, Cambridge, MA). This is an enzyme replacement therapy for ... Nature.com Препарат Cerezyme® Ñ?ффективен у пациентов Ñ? болезнью Гоше I … - Jan 18, 2007 КомпаниÑ? Genzyme Corporation Ñ?ообщила о публикации в Journal of Bone and Mineral Research результатов клиничеÑ?кого иÑ?Ñ?ледованиÑ? инъекционного препарата ... ФармацевтичеÑ?кий веÑ?тник Genzyme Reports Financial Results for the First Quarter of 2006. - Apr 19, 2006 There are approximately 4600 patients receiving Cerezyme worldwide. Cerezyme sales represent an increasingly smaller proportion of Genzyme's overall revenue ... Free with registration - PR Newswire - AccessMyLibrary.com New Genzyme fight fails to overshadow TKT comeback. - Jan 31, 2005 Now, Genzyme is seeking to guard Cerezyme, which has grown in sales every year ... Back to Cerezyme and TKT's early stage GA-GCB therapy for Gaucher's. ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude … - Jan 9, 2007 During this period, Genzyme's reliance on its first product, Cerezyme®, to sustain its ... Cerezyme sales in 2006 represented 32 percent of all revenue, ... webwire.com Genzyme is hungry - Oct 15, 2007 That one good asset is a drug now called Cerezyme. Together with its sister products, Cerezyme generated nearly half of Genzyme's $3.2 billion in revenue ... Daily Deal - The Daily Deal Genzyme Reports Financial Results for Fourth Quarter of 2005 and Full... - Feb 15, 2006 Sales of Cerezyme(R) (imiglucerase for injection) are expected to reach ... As Genzyme has long noted, Cerezyme is in a mature phase after 14 years on the ... $4.95 - PR Newswire - ECNext Отчет Genzyme за I квартал 2007 г. - Apr 27, 2007 Объем продаж компании выроÑ? на 21% и Ñ?оÑ?тавил 883,2 млн долл. СШÐ?. Ðтому Ñ?поÑ?обÑ?твовало увеличение объемов продаж препаратов Cerezyme, Fabrazyme и Renagel. ФармацевтичеÑ?кий веÑ?тник Genzyme: Δεκαπλάσια τα Îσοδα γ Ï„Ï?ιμήνου - Oct 24, 2007 Τα Îσοδα της Genzyme ενίσχυσαν ιδιαίτεÏ?α οι πωλήσεις του Ï€Ï?οϊόντος της Cerezyme και του νÎου της φαÏ?μάκου για κληÏ?ονομικÎÏ‚ ανωμαλίες. ... Reporter.gr Many With Gaucher Unaware of Disease - Dec 1, 2005 LaBelle receives intravenous infusions of the latest formulation of the enzyme, called Cerezyme, at a local Minneapolis hospital every other week. ... Jewish Journal of greater L.A - The Jewish Journal of greater L.A WHO'LL PAY FOR ORPHAN DRUGS? ; PATIENTS FEW, PRICES HIGH; … - Apr 22, 2007 In 2006, 4800 people worldwide were receiving Cerezyme, earning Genzyme more than $1 billion in annual revenue, said Dan Quinn, a company spokesman. ... Pay-Per-View - Hartford Courant - ProQuest Archiver Genzyme Profits Leap 58 Percent in Second Quarter - Jul 14, 2005 Though much of Genzyme's sales still come from Cerezyme, a treatment for a rare ... "It used to be a company of mainly Cerezyme, but now there's five or six ... RedOrbit FDA finds steel, rubber, other substances in Genzyme biotech drugs, … - May 28, 2008 The drugs affected by the latest announcement include: Cerezyme, Fabrazyme, Myozyme, ... The company's best-selling drug Cerezyme treats Gaucher disease, ... Los Angeles Times Event Brief of Q2 2007 Genzyme Corporation Earnings Conference Call -... - Jul 25, 2007 Cerezyme, over the past 13 years, continues to make a real. contribution to Co. ... On a YtoY basis, Cerezyme increased by almost $30m to $283m for 2Q07. 2. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Two New Gaucher Meds on Horizon - Aug 22, 2007 Scientists at Genzyme, the maker of Cerezyme, are working on a potential new oral ... Rather than providing additional enzyme, like Cerezyme, a substrate ... Forward Genzyme Corporation at Cowen and Company Annual Health Care … - Mar 13, 2007 And so, now Cerezyme is down to 32% in 2006 of total revenue. ... Cerezyme obviously has been in the market since the early '90s, is at a very stable stage, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: Genzyme Receives Approval for Additional Manufacturing... - Jul 24, 2006 Genzyme currently produces Cerezyme at its flagship manufacturing facility in Allston, MA. The company plans to use the Waterford facility for additional ... Pay-Per-View - PR Newswire - HighBeam Research Genzyme Beats, Holds to Lowered Guidance - Jul 23, 2008 However, sales of the company's lysosomal storage disorder drugs, Cerezyme, Fabrazyme and Myozyme all came in above expectations. ... TheStreet.com - TheStreet.com (subscription) Genzyme Reports Strong Fourth-Quarter Revenue Growth. - Jan 11, 2005 For the year, Cerezyme sales increased 14 percent to $839 million, ... In 2004, Cerezyme sales represented 38 percent of Genzyme's total revenue, ... $4.95 - PR Newswire - ECNext Genzyme Corporation Analyst Meeting - Final. - May 6, 2005 If gene therapy or small molecules can do better than Cerezyme -- and we will be ... And if that impacts the Cerezyme picture, we will accept that and make ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Shire drug gets FDA approval.(Elaprase) - Jul 25, 2006 Genzyme's success is built on Cerezyme, an enzyme replacement for a genetic ... Cerezyme is used by about 4500 patients worldwide and is expected to notch ... Free with registration - Boston Globe - AccessMyLibrary.com Preliminary Results From Phase 2 Genzyme Study Highlight Potential Of... - May 8, 2008 Genzyme's Cerezyme(R) (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous ... Medical News Today - Medical News Today (press release) Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full... - Feb 14, 2007 Sales of Cerezyme® (imiglucerase for injection) are expected to reach ... Cerezyme is the standard of care for patients with Type 1 Gaucher disease. ... webwire.com Biotech Ready to Deliver - Oct 11, 2005 Cerezyme, a Gaucher's disease treatment, is Genzyme's bestselling drug. Phil Nadeau of SG Cowen wrote in a recent research report that third-quarter ... TheStreet.com - TheStreet.com (subscription) Genzyme: Geared for Growth - Jun 11, 2007 Genzyme has largely grown through acquisitions, building around its Therapeutics division, particularly Cerezyme. The company has made five acquisitions ... BusinessWeek Genzyme diarrhea drug may be blockbuster - Feb 22, 2006 Eventually Myozyme could become as big a product as Cerezyme, which will generate sales of nearly $1 billion this year and has been on the market for more ... Reuters Kidney Worries Hit Genzyme | Althea Chang News | Print Financial & … - Apr 21, 2005 Enzyme replacement therapy Cerezyme led the pack in sales for the first quarter, ... Cerezyme is a treatment for Type 1 Gaucher disease, which causes fat ... TheStreet.com - TheStreet.com (subscription) Biotech Ready to Deliver - Oct 14, 2005 Cerezyme, a Gaucher's disease treatment, is Genzyme's bestselling drug. Phil Nadeau of SG Cowen wrote in a recent research report that third-quarter ... TheStreet.com - TheStreet.com (subscription) Novel Oral Compound Has Potential For Gaucher Disease - May 9, 2008 Genzyme's Cerezyme (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous ... emaxhealth.com Biotech majors face output woes - Apr 11, 2005 Cerezyme (imiglucerase), used to treat Gaucher's diseases, is one of four revenue drivers in Genzyme's genetic disorder franchise that further consists of ... ICIS Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 … - Dec 31, 2007 The study subjects on average were on ERT with Cerezyme(R) for ten years prior to entering this study. Preliminary data are available for the first twenty ... prnewswire.com Genzyme's Guerilla Informatics - Mar 14, 2006 A current project is work to optimize the second generation of Cerezyme. Manavalan's earlier models of Cerezyme's cysteine residues' susceptibility to ... Bio-IT World Medco to buy Accredo for $2.2 billion - Feb 23, 2005 For example, Cerezyme is a drug for Goucher disease, which affects 1400 people nationally. Cerezyme provides enzymes to help the body break down lipids, ... Bizjournals.com Genzyme 'bullish' on future growth - Jan 9, 2008 Treatments for rare hereditary disorders, including Cerezyme for Gaucher disease ... Fourth-quarter sales of Cerezyme increased 15 percent to $301 million. ... Boston Globe Generic Biotech Drugs Backed by US Senate Panel - Jun 27, 2007 ...s Cerezyme for Gaucher disease and Eli Lilly & Co. ... Cerezyme can cost $200000 a year. Biotech drugs use living cells, such as from bacteria or Chinese ... Bloomberg Genzyme Has Fourth-Quarter Loss; Sees Higher Sales - Feb 14, 2007 Sales of the Gaucher disease treatment, Cerezyme, are expected to reach $1.06 to $1.08 billion this year, up from $1 billion. People with Gaucher's lack an ... Bloomberg Research and Markets: Benchmark Genzymes Performance against Key … - Dec 15, 2006 Cerezyme Fabrazyme Hectorol Therapy area analysis, 2005-11 Other Hematology ... Cerezyme Overview Sales forecast Newsflow Competitive landscape Fabrazyme ... $4.95 - Business Wire - ECNext Press Release: A Competitor Analysis Report on Enzyme Replacement … - Dec 3, 2008 Genzymes Cerezyme and Ceredase enzyme replacement therapies are the only effective treatments for Gauchers disease, one of these disorders. ... Pay-Per-View - M2 Presswire - HighBeam Research Notable News in the Life Sciences: 1Q08 - Apr 22, 2008 ...but Cerezyme costs $300000 per year. It has been noted that many ... reduced dose of Cerezyme. This, however, fails to take into ... $1,500.00 - IDC - Alacra Store SAFETY FRAMES GENERICS DEBATE - May 27, 2007 For example, Cerezyme, a treatment for Gaucher disease, is made inside the ovarian cells of Chinese hamsters. "The key here in our mind is that everyone has ... Pay-Per-View - Palm Beach Post - NewsBank Press Release: BioMarin Announces Positive Results from Phase 3 Diet ... - Jan 17, 2007 BioMarin Announces Positive Results from Phase 3 Diet Study of Phenoptin and Study Show Genzyme's Cerezyme May Be Effective. from M2 Presswire. Pay-Per-View - M2 Presswire - HighBeam Research 'Orphan' Drugs Help Real People - Jul 12, 2008 Without the Orphan Drug Act, which enabled the development of Cerezyme (and ... Furthermore, the development of Cerezyme has led to similar drugs for the ... Subscription - Wall Street Journal Online - Dow Jones & Company … Phase 3 Diet Study of Phenoptin and Study Show Genzyme's Cerezyme ... - Jan 17, 2007 ...(Nasdaq: GENZ) is promoting results from a new clinical study that apparently validate long-term use of its enzyme replacement drug Cerezyme. ... $4.95 - M2 Presswire - ECNext Genzyme Profit Rises on Genetic-Disease Medicines - Oct 24, 2007 Cerezyme generated sales of $286.1 million, a 13 percent increase from $252.2 million a year earlier. Sales of Fabrazyme, for Fabry disease, ... Bloomberg Q&A: Genzyme's Alan Smith - Oct 4, 2005 Cerezyme was state-of-the-art 1980s technology. ... Q: Taking Cerezyme as an example, its predecessor, Ceredase, which was the first Genzyme product, ... Red Herring Epo, by any other name - Sep 20, 2007 This Editorial incorrectly states that the drug Cerezyme is produced by Genentech. It is, in fact, produced by Genzyme Therapeutics. Nature.com ОÑ?тановлен выпуÑ?к уникальных препаратов от редкого генетиче? - Jun 19, 2006 ЛекарÑ?тво Cerezyme длÑ? них выпуÑ?кает единÑ?твенный в мире фармацевтичеÑ?кий завод. Ð’ четверг порталы news. morningstar. com и bloomberg. com Ñ?ообщили, ... ГÐ?ЗЕТÐ?.GZT.ru 'Parents' needed for 'orphan' diseases - Aug 7, 2005 Mount Sinai Medical Center, who has had a key role in the development of orphan drugs, including Cerezyme for Gaucher's disease and Replagal for Fabry. ... Pay-Per-View - Jerusalem Post - ProQuest Archiver MKs, doctors seek 'parents' to adopt 'orphan diseases' - Jul 27, 2005 ...spoke about his role in the development of orphan drugs, which include Cerezyme for Gaucher's disease and Fabryzyme for [Fabry]'s disease. ... Pay-Per-View - Jerusalem Post - ProQuest Archiver Article: Phase II cancer drug trial methods are often obsolete.(Clinic... - Apr 1, 2007 Article: Protalix's Uplyso Hits Phase III Goals; Cerezyme ... BIOWORLD Today; October 16, 2009 ; 700+ words ... ... Inc. reported positive Phase III data ... Pay-Per-View - Skin & Allergy News - HighBeam Research Biotechbedrijf Genzyme richt zich op medicijnen voor zeldzame … - Nov 1, 2008 Het succesvolste medicijn van Genzyme is Cerezyme, dat vorig jaar 1,1 ... Cerezyme is een medicijn tegen de zeldzame stofwisselinsgziekte van Gaucher. ... MD Weekly SIMPOSIUM INTERNACIONAL SOBRE LAS ENFERMEDADES DE … - Mar 30, 2005 Entre los medicamentos de estas caracterÃsticas desarrollados por Genzyme están Cerezyme® (imiglucerasa) para la enfermedad de Gaucher, ... acceso.com Shell Firm Acquiring Protalix, Phase III Gaucher's Therapy - Aug 23, 2006 ...s Cerezyme (imiglucerase) - the only approved Gaucher's product, selling $254 million in the second quarter. The Protalix compound, due for Phase III this ... BioWorld Online - BioWorld Online Event Brief of Q1 2006 Genzyme Corporation Earnings Conference Call -... - Apr 19, 2006 Cerezyme, which increased by 6%, was driven largely by additional international patients. 3. Fabrazyme revenue was $81m and represented about 15% YtoY ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Event Brief of Q2 2006 Genzyme Corporation Earnings Conference Call -... - Jul 12, 2006 Although Cerezyme continues to be a strong product growing about 7%, other pipelines are growing ... Cerezyme in 2Q06 was only [13%] of total revenues. 8. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Brand Names/Synonyms: Cerezyme is also known by the following brand names and/or synonymsGlucosylceramidase precursor;Beta-glucocerebrosidase;Acid beta-glucosidase;D-glucosyl-N-acylsphingosine glucohydrolase;Alglucerase;Imiglucerase; Cerezyme (Genzyme Corp); Ceredase (Genzyme) Drug Category: Cerezyme is categorized under the following by the FDA: Enzyme replacement; enzymes (44:00.00) Dosage Forms: POWDER FOR SOLUTION Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Human Beta-glucocerebrosidase |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
